Discontinuation report MINT-RIVASTIGMINE
Report ID | 13562 |
Drug Identification Number | 02406985 |
Brand name | MINT-RIVASTIGMINE |
Common or Proper name | Rivastigmine |
Company Name | MINT PHARMACEUTICALS INC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | RIVASTIGMINE |
Strength(s) | 1.5MG |
Dosage form(s) | CAPSULE |
Route of administration | ORAL |
Packaging size | Blister pack of 56 capsules. |
ATC code | N06DA |
ATC description | ANTI-DEMENTIA DRUGS |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | |
Actual discontinuation date | 2017-06-30 |
Remaining supply date | 2017-06-30 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 6575 DAVAND DRIVE MISSISSAUGA, ONTARIO CANADA L5T 2M3 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2017-07-01 | English | Compare |
v2 | 2017-06-21 | French | Compare |
v1 | 2017-06-21 | English | Compare |
Showing 1 to 3 of 3